Memantine OD is safe: Forest
Forest Lab said on Tuesday that patients in a late-stage clinical trial who took a once-daily formulation of its Alzheimer's drug Namenda (Meantime Hydrochloride) had a significant improvement in symptoms compared with those who took a placebo.
The company, which already sells a twice-daily formulation of the drug, evaluated the efficacy and safety of an extended release version of the drug in patients with moderate to severe Alzheimer's disease currently treated with a drug in the class known as cholinesterase inhibitors.
The company said that based on the results, which showed marked improvement in certain tests of mental function, it will pursue a marketing application for the drug.
Glenmark license anti-asthmatic drug to Forest
Glenmark received $15 million from Forest Lab as part payment for an asthma drug it licensed to the U.S.- based company in 2004. Glenmark got the so-called milestone payment after the USFDA allowed Forest to conduct additional phase 2 trials on humans for the drug GRC3886, or oglemilast. Glenmark, which earlier received $10 million from Forest, expects to get as much as $190 million as milestone payments for the asthma treatment, if it is successful. Glenmark said on Feb. 1 its agreement with a unit of Germany's Merck KGaA to develop a diabetes drug had ended and that it would continue trials on the treatment on its own, a move that could increase its research costs. Glenmark has also licensed oglemilast to Japan's Teijin Pharma Ltd. for development and sale in Japan and is seeking to license the drug to companies in Europe
Forest Lab said on Tuesday that patients in a late-stage clinical trial who took a once-daily formulation of its Alzheimer's drug Namenda (Meantime Hydrochloride) had a significant improvement in symptoms compared with those who took a placebo.
The company, which already sells a twice-daily formulation of the drug, evaluated the efficacy and safety of an extended release version of the drug in patients with moderate to severe Alzheimer's disease currently treated with a drug in the class known as cholinesterase inhibitors.
The company said that based on the results, which showed marked improvement in certain tests of mental function, it will pursue a marketing application for the drug.
Glenmark license anti-asthmatic drug to Forest
Glenmark received $15 million from Forest Lab as part payment for an asthma drug it licensed to the U.S.- based company in 2004. Glenmark got the so-called milestone payment after the USFDA allowed Forest to conduct additional phase 2 trials on humans for the drug GRC3886, or oglemilast. Glenmark, which earlier received $10 million from Forest, expects to get as much as $190 million as milestone payments for the asthma treatment, if it is successful. Glenmark said on Feb. 1 its agreement with a unit of Germany's Merck KGaA to develop a diabetes drug had ended and that it would continue trials on the treatment on its own, a move that could increase its research costs. Glenmark has also licensed oglemilast to Japan's Teijin Pharma Ltd. for development and sale in Japan and is seeking to license the drug to companies in Europe
